While AR-targeting therapies have become a mainstay in the treatment of prostate cancers, ongoing preclinical and clinical studies in AR+ tumours have demonstrated therapeutic potential for the treatment of AR+ breast cancers using AR antagonists. This evidence concerns the gene AR and Familial prostate cancer.